WELCOME TO

Pronidesivir Tablets Official Site

MiaiteNeoFipronis

Pronidesivir Tablets Official Site

MiaiteNeoFipronis

News & Articles

News & Articles

Clarification on the Non-Prescription Veterinary Status of NeoFipronis® (Pronidesivir) in Laos

NeoFipronis® (Pronidesivir) has been officially registered in Laos as a non-prescription veterinary medicine. The product contains GS-441524 and is formulated as oral tablets for feline infectious peritonitis (FIP)-related treatment management.Vientiane, Laos — April 28, 2026 — Recently, some cat owners and partners have misunderstood NeoFipronis® (Pronidesivir) as a prescription-only medicine. To avoid confusion, NeoFipronis® provides the following clarification regarding the product’s regulatory status in Laos.NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is its active ingredient. The product has completed official registration in Laos and has been approved as a non-prescription veterinary medicine. It is available through authorized channels.However, non-prescription veterinary status does not mean the product should be used casually or without proper consideration. Feline infectious peritonitis, commonly known as FIP, is a complex and serious feline disease. Diagnosis and treatment management should take into account clinical signs, body weight, laboratory results, imaging findings, and professional veterinary judgment.Therefore, even though NeoFipronis® (Pronidesivir) has been approved in Laos as a non-prescription veterinary medicine, cat owners are still encouraged to consult a licensed veterinarian or qualified animal health professional before use.NeoFipronis® (Pronidesivir) is formulated as oral tablets and is designed to provide a more convenient, traceable, and quality-controlled oral GS-441524 veterinary product option for FIP-related treatment management. Compared with products of unclear origin or unverified quality, products obtained through authorized channels help support authenticity, batch traceability, and quality consistency.It is important to note that regulatory status, sales authorization, and permitted use of GS-441524-related products may vary by country or region. The non-prescription veterinary status of NeoFipronis® (Pronidesivir) in Laos does not mean that the product has the same regulatory status in every market. Cat owners, veterinarians, and partners should understand and comply with applicable local regulations before purchasing or using the product.NeoFipronis® will continue to improve its product information system around “official registration, legitimate source, batch traceability, and quality control.” The website will provide product information, usage guidance, authorized-channel information, and verification support to help cat owners and veterinarians better understand NeoFipronis® (Pronidesivir).Important NoticeNeoFipronis® (Pronidesivir) has been approved in Laos as a non-prescription veterinary medicine. However, FIP diagnosis, dosage planning, treatment duration, and monitoring should still be based on professional veterinary evaluation. Cat owners should not judge the condition based on a single symptom alone, nor should they adjust the dosage or discontinue treatment without professional advice.

Read More »

04/28/2026

NeoFipronis® (Pronidesivir) Officially Launched as an Oral GS-441524 Tablet for FIP Treatment

Containing GS-441524, NeoFipronis® (Pronidesivir) provides convenient oral administration, batch traceability, and quality-control support for cats with feline infectious peritonitis.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has officially launched as an oral GS-441524 veterinary tablet for cats with feline infectious peritonitis, commonly known as FIP.NeoFipronis® (Pronidesivir) has been officially registered in Laos and is now available through authorized channels. The launch marks an important step toward providing a more standardized, traceable, and quality-controlled oral GS-441524 veterinary product for FIP treatment.During FIP treatment, long-term, regular, and consistent medication management is essential. Traditional injectable options may cause pain, stress, and handling challenges for cats, while also increasing the difficulty of daily administration for cat owners. NeoFipronis® (Pronidesivir) is formulated as an oral tablet to help improve dosing convenience during long-term treatment.NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is its active ingredient. The product is manufactured under controlled quality standards and supports batch traceability and product verification, helping reduce quality and safety risks associated with non-standard or unauthorized products.NeoFipronis® (Pronidesivir) focuses not only on the product itself, but also on information transparency and standardized use throughout the FIP treatment process. Pronidesivir.com, the official website of NeoFipronis® (Pronidesivir), will continue to provide product information, frequently asked questions, usage guidance, batch inquiry, and authorized-channel information to help cat owners better understand the product.The launch of NeoFipronis® (Pronidesivir) represents an important step in promoting the standardization of FIP treatment products. The brand will continue to build long-term support around product quality, veterinary guidance, reliable information, and user assistance.

Read More »

03/02/2026

NeoFipronis® (Pronidesivir) Officially Introduced, Focusing on Feline Infectious Peritonitis Treatment

As an oral veterinary product containing GS-441524, NeoFipronis® (Pronidesivir) is committed to providing a more convenient, transparent, and traceable oral GS-441524 product option for cats with FIP.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has been officially introduced as an oral GS-441524 veterinary product focused on feline infectious peritonitis (FIP).NeoFipronis® (Pronidesivir) has been officially registered in Laos and is available through authorized channels. The product is designed to support a more standardized, traceable, and quality-controlled oral veterinary product option for FIP-related treatment management.NeoFipronis® is the brand name of Pronidesivir. The product uses GS-441524 as its active ingredient and is formulated as oral tablets, aiming to meet the medication needs of cats with FIP during long-term treatment under veterinary guidance.Feline infectious peritonitis is a serious disease associated with mutations of feline coronavirus. It may present with clinical signs such as abdominal effusion, pleural effusion, persistent fever, loss of appetite, weight loss, ocular symptoms, or neurological symptoms. Diagnosis and treatment of FIP require consideration of clinical signs, laboratory testing, imaging findings, and professional veterinary judgment.The introduction of NeoFipronis® (Pronidesivir) focuses on addressing several key concerns commonly raised by cat owners regarding FIP-related products: whether the product source is legitimate, whether the ingredients are clearly defined, whether each batch is traceable, whether quality is controlled, and whether the medication is convenient for long-term administration.NeoFipronis® will continue to improve its product trust system around “official registration, legitimate source, batch traceability, and quality control.” The website will provide product information, instructions for use, authorized-channel information, and verification support to help cat owners and veterinarians better understand the product.

Read More »

03/02/2026

NeoFipronis® (Pronidesivir) Completes Official Registration in Laos, Advancing the Standardization of FIP Treatment Products

Containing GS-441524 in an oral tablet form, NeoFipronis® (Pronidesivir) provides a quality-controlled and traceable veterinary product option for feline infectious peritonitis (FIP)-related treatment management.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has completed official registration in Laos and is now available through authorized channels as an oral GS-441524 veterinary tablet.This official registration represents an important milestone in the development of NeoFipronis® (Pronidesivir), reflecting continued commitment to product standardization, quality control, and batch traceability.NeoFipronis® is the brand name of Pronidesivir. As an oral veterinary product containing GS-441524, NeoFipronis® (Pronidesivir) is designed to support cats with feline infectious peritonitis (FIP) under veterinary guidance, while helping veterinarians and cat owners access a clearer and more verifiable product source.For many years, FIP-related treatment products have faced challenges such as unclear product sources, inconsistent quality standards, and limited dosage transparency. Through official registration, batch traceability, and authorized-channel supply, NeoFipronis® (Pronidesivir) aims to reduce the potential risks associated with non-standard or unauthorized products.The product is formulated as oral tablets and may be used under veterinary guidance according to the cat’s body weight, clinical type, and changes in condition. Compared with injectable formulations, oral tablets may help improve dosing convenience during long-term treatment and reduce daily administration stress for cats.NeoFipronis® will continue to improve its product quality system, batch verification mechanism, and professional information support to provide more reliable product information and user support for the FIP treatment field.

Read More »

03/02/2026

NeoFipronis® (Pronidesivir) Oral GS-441524 Tablets Officially Launched

Officially registered in Laos, NeoFipronis® (Pronidesivir) provides a traceable, quality-controlled oral GS-441524 veterinary product option for cats with feline infectious peritonitis.Vientiane, Laos — March 2, 2026 — NeoFipronis® (Pronidesivir) has officially launched as an oral GS-441524 veterinary tablet for cats with feline infectious peritonitis, commonly known as FIP.NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is the active pharmaceutical ingredient. The product has been officially registered in Laos and is now available through authorized channels, marking an important step toward a more standardized, traceable, and quality-controlled approach to FIP-related treatment management.Feline infectious peritonitis is a serious and life-threatening disease in cats. For many years, FIP was considered one of the most difficult feline diseases to manage. With the development and clinical application of GS-441524, FIP treatment has entered a new stage, giving veterinarians and cat owners more options for managing this challenging disease.NeoFipronis® (Pronidesivir) Oral Tablets are designed for convenient oral administration during FIP treatment. Compared with injectable options, oral tablets may help reduce stress for cats and improve daily administration compliance during longer treatment courses.Each batch of NeoFipronis® (Pronidesivir) is manufactured under controlled quality standards and supported by batch traceability and product verification. This helps veterinarians, distributors, and cat owners identify authentic products and reduce the risks associated with unverified or unauthorized sources.The launch of NeoFipronis® (Pronidesivir) reflects a continued commitment to providing a reliable, traceable, and veterinarian-guided oral GS-441524 product option for cats affected by FIP.FIP diagnosis, dosage planning, treatment duration, and monitoring should be guided by a licensed veterinarian or qualified animal health professional. Treatment decisions should be based on the cat’s clinical condition, body weight, laboratory results, disease type, and professional veterinary judgment.Cat owners and partners are encouraged to purchase products only through authorized channels. Unverified products may carry risks such as inconsistent composition, inaccurate dosage, lack of traceability, or uncertain quality.With the official launch of NeoFipronis® (Pronidesivir), the brand aims to support a more transparent, standardized, and quality-focused approach to FIP-related treatment access.

Read More »

03/02/2026

FIP Symptoms, Diagnosis, and Treatment | Complete Guide to Feline Infectious Peritonitis (FIP) Prevention and Care

IntroductionFeline Infectious Peritonitis (FIP) is one of the most complex and concerning diseases in feline medicine. Caused by a mutated feline coronavirus (FCoV), FIP can progress rapidly and affect multiple organs, leading to severe illness. For years, it was regarded as an incurable condition, but with the introduction of advanced antiviral therapies, effective treatment is now possible. This guide explains FIP symptoms, how the disease is diagnosed, the treatment options available, and essential prevention strategies for cat owners.1. Recognizing Symptoms of FIPSymptoms of FIP vary depending on whether the cat has the effusive (wet) form or the non-effusive (dry) form.Wet (Effusive) FIP: Characterized by fluid buildup in the abdomen or chest. Cats may have swollen bellies, difficulty breathing, persistent fever, lethargy, and weight loss.Dry (Non-Effusive) FIP: More challenging to detect. Symptoms include neurological problems such as seizures, imbalance, or paralysis; eye changes like uveitis or retinal lesions; chronic fever; and gradual weight loss.General Signs: Poor appetite, depression, anemia, and chronic inflammation. Early symptoms may resemble other illnesses, so careful evaluation is essential.2. How FIP Is DiagnosedThere is no single definitive test for FIP. Instead, veterinarians rely on a combination of medical history, physical examination, and laboratory findings.Blood Tests: High globulin levels, low albumin-to-globulin ratio, anemia, and elevated white blood cell counts are common.Fluid Analysis: In effusive FIP, fluid from the chest or abdomen is examined. FIP fluid is typically thick, yellow, and protein-rich.Imaging: Ultrasound or X-rays can detect fluid accumulation, enlarged lymph nodes, or organ involvement.PCR Testing: Detects coronavirus RNA, though a positive result does not always mean FIP.Clinical Evaluation: Veterinarians combine test results with clinical signs to reach a presumptive diagnosis.3. Treatment Options for FIPThe biggest breakthrough in FIP treatment has been the development of antiviral drugs that inhibit viral replication.GS-441524: A nucleoside analog proven highly effective in blocking viral replication. Survival rates in treated cats now exceed 80–90%.Pronidesivir (NeoFipronis®): An oral formulation of GS-441524 specifically designed for veterinary use. Easier to administer and less stressful for cats compared to injections.Remdesivir: Used in some countries as an alternative, since it metabolizes into GS-441524 in the body.Treatment Duration: Typically requires 12 weeks of continuous therapy, with dosages adjusted for weight and disease severity. Neurological or ocular cases require higher dosages.4. Supportive Care During TreatmentAntivirals are the cornerstone, but supportive measures enhance recovery and improve quality of life.Nutritional Support: High-quality, protein-rich diets help maintain body weight and strength.Immune Support: Taurine, omega-3 fatty acids, probiotics, and vitamins support general health.Anti-inflammatory Medications: Used selectively to reduce severe inflammation, though less critical with effective antiviral treatment available.Symptom Management: Intravenous fluids, appetite stimulants, or antibiotics may be used as needed.5. Monitoring and Follow-UpDuring and after treatment, regular veterinary check-ups are essential.Blood Monitoring: CBC and biochemical tests every few weeks to assess response and detect organ stress.Weight Tracking: Weight gain indicates positive response to treatment.Neurological Assessments: In dry FIP cases with neurological involvement, progress must be monitored closely.Post-Treatment Surveillance: Even after completing the full course, periodic checks ensure no relapse occurs.6. Prevention of FIPSince not every coronavirus infection leads to FIP, prevention focuses on reducing viral load and supporting immunity.Hygiene: Keep litter boxes clean and reduce overcrowding in multi-cat households.Stress Reduction: Cats in low-stress environments have stronger immune defenses.Cattery Management: Breeders must avoid high-density housing and monitor breeding lines for FIP history.Wellness Care: Regular veterinary visits and balanced nutrition strengthen resilience against infection.7. The Future of FIP ResearchThe future is optimistic. Ongoing research aims to refine antiviral drugs, develop safe vaccines, and explore combination therapies for more complex cases. With more veterinary-approved products like Pronidesivir becoming available, treatment will become more accessible and standardized.ConclusionFIP has transformed from a fatal disease into a treatable condition thanks to modern antiviral therapy. By recognizing symptoms early, ensuring accurate diagnosis, and committing to full-course treatment, cat owners can provide their pets with a real chance at recovery. Combined with preventive care, these advances bring new hope for cats worldwide.

Read More »

08/21/2025

INDICATION AND IMPORTANT SAFETY INFORMATION

WHAT IS NEOFIPRONIS® (Pronidesivir)?

NeoFipronis® (Pronidesivir) is a non-prescription veterinary medicine used for the treatment of feline infectious peritonitis (FIP) in cats. It is indicated for all known forms of FIP, including effusive (wet), non-effusive (dry), neurological, and ocular types.

The active ingredient in NeoFipronis® is GS‑441524, a nucleoside analog widely known for its potent antiviral activity against feline coronaviruses. Its official International Nonproprietary Name (INN) is Pronidesivir.

NeoFipronis® (Pronidesivir) is not approved for use in humans and should only be administered to cats. Use under the guidance of a licensed veterinarian is strongly recommended.

Do not exceed the recommended daily dosage. Overdosing may increase the risk of adverse effects, including liver or kidney strain.

IMPORTANT SAFETY INFORMATION

Before giving NeoFipronis® (Pronidesivir) to your cat, tell your veterinarian if your cat:

  • Is under 4 weeks of age
  • Is pregnant or suspected to be pregnant
  • Has known liver or kidney disease
  • Is receiving other medications, supplements, or undergoing concurrent treatment

Using NeoFipronis® (Pronidesivir) with other medications may alter its effectiveness or increase the risk of interactions. Always inform your veterinarian of any other treatments your cat is receiving.

The standard dose is 15mg/kg orally once daily on an empty stomach. Higher doses (up to 30mg/kg) may be needed for cats with neurological or ocular FIP. Do not change the dosage without veterinary advice.

What are the possible side effects of NeoFipronis® (Pronidesivir) ?

The most commonly observed side effects include vomiting, loss of appetite, lethargy, and mild gastrointestinal discomfort. These effects are generally manageable and reversible. Serious adverse effects are rare when used as directed.

Regular monitoring of your cat’s bloodwork—including liver and kidney function—is recommended during treatment. Discontinue use and contact your veterinarian immediately if serious reactions occur.

Talk to your veterinarian for medical advice about side effects or concerns regarding treatment.

NeoFipronis® (Pronidesivir) is a non-prescription veterinary medicine, and its use under veterinary supervision is strongly recommended.

Keep out of reach of children and animals. Not for human use.

For full prescribing information and product details, please visit:www.pronidesivir.com.